Direct Acting Antiviral (DAA) Based Therapy for Recently Acquired Hepatitis C
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DARE-C
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 01 Sep 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.